Atypical Antipsychotic Comparison
Risperidone · Olanzapine — Similarities, differences, and available strengths
| Risperdal (risperidone) | Zyprexa (olanzapine) | |
|---|---|---|
| Drug class | Atypical antipsychotic | Atypical antipsychotic |
| FDA indications | Schizophrenia; bipolar mania; irritability associated with autism spectrum disorder | Schizophrenia; bipolar I (acute manic/mixed); bipolar depression (with fluoxetine) |
| Available oral strengths |
0.25 mg
0.5 mg
1 mg
2 mg
3 mg
4 mg
Also: oral solution 1 mg/mL; ODT (M-Tab) 0.25–4 mg |
2.5 mg
5 mg
7.5 mg
10 mg
15 mg
20 mg
Also: Zydis ODT 5, 10, 15, 20 mg; IM injection |
| Long-acting injectable | Risperdal Consta — 12.5, 25, 37.5, 50 mg (every 2 weeks) | Zyprexa Relprevv — 150, 210, 300, 405 mg (every 2–4 weeks) |
| Weight gain risk | Moderate | Highest of all atypicals |
| Metabolic risk | Moderate — monitor glucose and lipids | High — significant risk of diabetes and dyslipidemia |
| EPS / akathisia risk | Higher — dose-dependent EPS, akathisia common | Low — favourable EPS profile |
| Prolactin elevation | Significant — among the highest of atypicals | Minimal |
| Sedation | Mild to moderate | High — strong sedative effect |
| Mechanism | D₂ / 5-HT₂A antagonist | D₂ / 5-HT₂A antagonist + strong anticholinergic, antihistamine activity |
| Generic available | Yes | Yes |
Risperdal (risperidone)
Zyprexa (olanzapine)
Olanzapine (Zyprexa) is consistently ranked as the atypical antipsychotic with the highest risk for clinically significant weight gain, new-onset type 2 diabetes, and dyslipidemia. Monitoring of weight, fasting glucose, and lipid panels is especially critical. Risperidone carries moderate metabolic risk — less than olanzapine, but more than aripiprazole or ziprasidone.
Risperidone is more tightly bound to D₂ receptors than olanzapine, giving it a higher risk of extrapyramidal side effects (muscle stiffness, tremor, akathisia) in a dose-dependent fashion. It is also among the strongest prolactin elevators of any atypical antipsychotic, potentially causing galactorrhea, menstrual irregularities, and sexual dysfunction. Olanzapine's looser D₂ binding results in low EPS risk and minimal prolactin elevation.
Olanzapine's strong antihistamine (H₁) and anticholinergic properties make it substantially more sedating than risperidone. This sedation can be therapeutically useful in acute agitation but may impair daytime functioning. Risperidone produces mild-to-moderate sedation, particularly at higher doses.
Both agents have long-acting injectable (LAI) formulations for patients with adherence challenges. Risperdal Consta (every 2 weeks) has a longer track record; Zyprexa Relprevv (every 2–4 weeks) carries a unique post-injection delirium/sedation syndrome risk requiring 3-hour observation periods after each injection.
Both are atypical antipsychotics that block dopamine D₂ and serotonin 5-HT₂A receptors. Their key differences lie in side effect profiles: Zyprexa (olanzapine) carries the highest weight gain and metabolic risk of all atypical antipsychotics, with significant risks for diabetes and dyslipidemia. Risperdal (risperidone) has comparatively lower metabolic risk but a higher risk of extrapyramidal symptoms (EPS) and significantly elevated prolactin levels.
Zyprexa (olanzapine) causes significantly more weight gain than Risperdal (risperidone). In comparative trials and meta-analyses, olanzapine consistently produces the most weight gain of any atypical antipsychotic, often exceeding 10 lbs in the first few months of treatment. Risperidone produces moderate weight gain — less than olanzapine, more than aripiprazole.
Yes. Risperdal (risperidone) has a higher risk of extrapyramidal side effects (EPS), including akathisia (inner restlessness), parkinsonian symptoms, and tardive dyskinesia with long-term use. This risk increases with higher doses. Zyprexa (olanzapine) has a considerably lower EPS risk due to its weaker D₂ receptor binding and faster dissociation.
Yes. Risperidone is one of the atypical antipsychotics with the strongest prolactin-elevating effect, comparable in magnitude to many typical antipsychotics. Elevated prolactin can cause galactorrhea (breast milk production), menstrual irregularities, gynecomastia, and sexual dysfunction. Zyprexa (olanzapine) has minimal impact on prolactin levels.
Zyprexa (olanzapine) is considerably more sedating than Risperdal (risperidone). Olanzapine's strong H₁ antihistamine and anticholinergic activity produces marked sedation that can be helpful during acute psychiatric episodes but may impair daytime alertness and cognitive function with continued use. Risperidone causes mild to moderate sedation.
Yes. Both Risperdal and Zyprexa carry an FDA black box warning stating that elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death (from cardiovascular or infectious causes). Neither drug is approved for dementia-related psychosis.
Risperdal oral tablets: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. An oral solution (1 mg/mL) and orally disintegrating M-Tab tablets are also available in the same strengths. The long-acting injectable Risperdal Consta comes in 12.5 mg, 25 mg, 37.5 mg, and 50 mg vials, given by IM injection every two weeks.
Zyprexa oral tablets: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg. Zyprexa Zydis orally disintegrating tablets are available in 5 mg, 10 mg, 15 mg, and 20 mg. An intramuscular injection (10 mg/vial) is used for acute agitation. The long-acting injectable Zyprexa Relprevv is available in 150 mg, 210 mg, 300 mg, and 405 mg vials.